Literature DB >> 22736080

CNS demyelination in fibrodysplasia ossificans progressiva.

Lixin Kan1, Joseph A Kitterman, Daniele Procissi, Salin Chakkalakal, Chian-Yu Peng, Tammy L McGuire, Robert E Goldsby, Robert J Pignolo, Eileen M Shore, Frederick S Kaplan, John A Kessler.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder of progressive heterotopic ossification (HO) caused by a recurrent activating mutation of ACVR1/ALK2, a bone morphogenetic protein (BMP) type I receptor. FOP is characterized by progressive HO, which is associated with inflammation in the setting of dysregulated BMP signaling, however, a variety of atypical neurologic symptoms are also reported by FOP patients. The main objective of this study is to investigate the potential underlying mechanism that is responsible for the observed atypical neurologic symptoms. We evaluated two mouse models of dysregulated BMP signaling for potential CNS pathology through non-invasive magnetic resonance imaging (MRI) studies and histological and immunohistochemical approaches. In one model, BMP4 is over-expressed under the control of the neuron-specific enolase promoter; the second model is a knock-in of a recurrent FOP mutation of ACVR1/ALK2. We also retrospectively examined MRI scans of four FOP patients. We consistently observed demyelinated lesions and focal inflammatory changes of the CNS in both mouse models but not in wild-type controls, and also found CNS white matter lesions in each of the four FOP patients examined. These findings suggest that dysregulated BMP signaling disturbs normal homeostasis of target tissues, including CNS where focal demyelination may manifest as the neurologic symptoms frequently observed in FOP.

Entities:  

Mesh:

Year:  2012        PMID: 22736080      PMCID: PMC3894630          DOI: 10.1007/s00415-012-6563-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

Review 1.  Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Curr Osteoporos Rep       Date:  2011-06       Impact factor: 5.096

2.  Substance P signaling mediates BMP-dependent heterotopic ossification.

Authors:  Lixin Kan; Vitali Y Lounev; Robert J Pignolo; Lishu Duan; Yijie Liu; Stuart R Stock; Tammy L McGuire; Bao Lu; Norma P Gerard; Eileen M Shore; Frederick S Kaplan; John A Kessler
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

3.  Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.

Authors:  Gin-Ah Song; Hyun-Jung Kim; Kyung-Mi Woo; Jeong-Hwa Baek; Gwan-Shik Kim; Jin-Young Choi; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

4.  Modulation of bone morphogenic protein signalling alters numbers of astrocytes and oligodendroglia in the subventricular zone during cuprizone-induced demyelination.

Authors:  Holly S Cate; Jennifer K Sabo; Daniel Merlo; Dennis Kemper; Tim D Aumann; Julien Robinson; Toby D Merson; Ben Emery; Victoria M Perreau; Trevor J Kilpatrick
Journal:  J Neurochem       Date:  2010-10       Impact factor: 5.372

5.  Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions.

Authors:  Jennifer K Sabo; Tim D Aumann; Daniel Merlo; Trevor J Kilpatrick; Holly S Cate
Journal:  J Neurosci       Date:  2011-03-23       Impact factor: 6.167

6.  Transgenic overexpression of BMP4 increases astroglial and decreases oligodendroglial lineage commitment.

Authors:  William A Gomes; Mark F Mehler; John A Kessler
Journal:  Dev Biol       Date:  2003-03-01       Impact factor: 3.582

7.  Neurological symptoms in individuals with fibrodysplasia ossificans progressiva.

Authors:  Joseph A Kitterman; Jonathan B Strober; Lixin Kan; David M Rocke; Amanda Cali; Jeannie Peeper; Jennifer Snow; Patricia L R Delai; Rolf Morhart; Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  J Neurol       Date:  2012-06-30       Impact factor: 4.849

8.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

9.  The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.

Authors:  Qi Shen; Shawn C Little; Meiqi Xu; Julia Haupt; Cindy Ast; Takenobu Katagiri; Stefan Mundlos; Petra Seemann; Frederick S Kaplan; Mary C Mullins; Eileen M Shore
Journal:  J Clin Invest       Date:  2009-10-12       Impact factor: 14.808

Review 10.  Fibrodysplasia ossificans progressiva: clinical and genetic aspects.

Authors:  Robert J Pignolo; Eileen M Shore; Frederick S Kaplan
Journal:  Orphanet J Rare Dis       Date:  2011-12-01       Impact factor: 4.123

View more
  22 in total

1.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

Review 2.  Fibrodysplasia ossificans progressiva: a current review of imaging findings.

Authors:  Adam H Bauer; Jeff Bonham; Luis Gutierrez; Edward C Hsiao; Daria Motamedi
Journal:  Skeletal Radiol       Date:  2018-02-14       Impact factor: 2.199

3.  Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.

Authors:  Frederick S Kaplan; Joyce A Kobori; Carmen Orellana; Inmaculada Calvo; Monica Rosello; Francisco Martinez; Berta Lopez; Meiqi Xu; Robert J Pignolo; Eileen M Shore; Jay C Groppe
Journal:  Am J Med Genet A       Date:  2015-06-11       Impact factor: 2.802

4.  Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis.

Authors:  Daniele De Brasi; Francesca Orlando; Valeria Gaeta; Maria De Liso; Fabio Acquaviva; Luigi Martemucci; Augusto Mastrominico; Maja Di Rocco
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

5.  An ACVR1 activating mutation causes neuropathic pain and sensory neuron hyperexcitability in humans.

Authors:  Xiaobing Yu; Amy N Ton; Zejun Niu; Blanca M Morales; Jiadong Chen; Joao Braz; Michael H Lai; Emilie Barruet; Hongju Liu; Kin Cheung; Syed Ali; Tea Chan; Katherine Bigay; Jennifer Ho; Ina Nikolli; Steven Hansberry; Kelly Wentworth; Arnold Kriegstein; Allan Basbaum; Edward C Hsiao
Journal:  Pain       Date:  2022-04-20       Impact factor: 7.926

Review 6.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

Review 7.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

Review 8.  Molecular mechanisms of heterotopic ossification.

Authors:  Lee M Reichel; Elizabeth Salisbury; Michael J Moustoukas; Alan R Davis; Elizabeth Olmsted-Davis
Journal:  J Hand Surg Am       Date:  2013-11-15       Impact factor: 2.230

Review 9.  ACVR1 mutations in DIPG: lessons learned from FOP.

Authors:  Kathryn R Taylor; Maria Vinci; Alex N Bullock; Chris Jones
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701

Review 10.  Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva.

Authors:  Fatima Khan; Xiaobing Yu; Edward C Hsiao
Journal:  Biomedicines       Date:  2021-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.